Predicting the severity of covid-19 infection through the concentration of c-reactive protein as a primary inflammatory marker

Previous literature studies have reported that clinical presentation and pathology of the novel coronavirus resembled SARS and MERS in regards to the elevated levels of Interleukin-6, through cellular transcription. This study aims to explore the clinical value of C-reactive Protein as a primary inflammatory marker to assess the severity of the disease. Meta-analysis is performed to investigate the association of the clinical manifestation of CRP1 with disease aggravation in a collective of published clinical findings and evaluate the CRP content as a potential biomarker to predict disease severity. The recent literature databases utilized to study the epidemiology of the SARS-CoV-2 strain and CRP accumulation include PubMed, The Lancet, NCBI2, Researchgate, and Medscape. In this retrospective cohort study, a clinical index is constructed with the clinical characteristics of 120 RT-PCR3 confirmed positive patients enrolled from December to February 2020 in China, South Korea, United Kingdom, and France. Calculations for relative weight values of each study and statistical analysis were performed using the inverse variance method. As unabated cytokine storms have correlated with greater risks of chronic lung diseases, CRP blood test as a type of inflammatory marker may serve as a measure of detecting IL-64 content in a patient displaying symptoms of COVID-19. Through this study, a definite association between inflammation and severity of Coronavirus was recognized and evaluated. Hence, this study proposes inflammatory markers such as CRP blood test as a guideline for optimal allocation of antibody test kits in the United States where a dearth of these resources exist.